Dihydroergotamine (Atzumi) vs Dihydroergotamine mesylate (Brekiya)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: 5-HT1D receptor · full Migraine pipeline

Dihydroergotamine (Atzumi)

Marketed by Shin Nippon Biomedical Laboratories and partners

Approved in Migrainesmall molecule
Partial signal

NCT04940390 · Phase 3 · completed

SUMMIT was a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 1,591 migraine patients, with 1,424 in the modified intent-to-treat analysis. Its two co-primary endpoints were freedom from pain and freedom from the most bothersome symptom at 2 hours. STS101 5.2 mg gave numerically higher rates than placebo on both, but the sponsor states that the differences did not achieve statistical significance, so the primary endpoints were missed. The counts come from the ClinicalTrials.gov posted results and the call from Satsuma's topline release.

Significance call from the sponsor's topline release; the posted registry results give counts without a statistical analysis.

Reported efficacy

Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose (2 Hours Post-Dose); Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose (2 Hours Post-Dose): Co-primary endpoints at 2 hours, STS101 5.2 mg (n=716) vs placebo (n=708), mITT: freedom from pain 146/716 (20.4%) vs 124/708 (17.5%); freedom from most bothersome symptom 265/716 (37.0%) vs 230/708 (32.5%). The sponsor states the differences did not reach statistical significance; no p-values are reported. (missed)

Result source: NCT04940390

Dihydroergotamine mesylate (Brekiya)

Marketed by Amneal Pharmaceuticals

Approved in Migrainesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Dihydroergotamine mesylate (Brekiya): no structured comparison results are available for Migraine.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Dihydroergotamine (Atzumi)
Co-primary endpoints at 2 hours, STS101 5.2 mg (n=716) vs placebo (n=708), mITT: freedom from pain 146/716 (20.4%) vs 124/708 (17.5%); freedom from most bothersome symptom 265/716 (37.0%) vs 230/708 (32.5%). The sponsor states the differences did not reach statistical significance; no p-values are reported. NCT04940390 · Phase 3 · design grade: moderate · publication or press release
Co-primary endpoints at 2 hours, STS101 3.9 mg (n=354) and 5.2 mg (n=353) vs placebo (n=358), mITT: freedom from pain 69/354 (19.5%) and 68/353 (19.3%) vs 53/358 (14.8%); freedom from most bothersome symptom 133/354 (37.6%) and 139/353 (39.4%) vs 119/358 (33.2%). The sponsor states neither dose was statistically significant on either co-primary endpoint; no p-values are reported. NCT03901482 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dihydroergotamine (Atzumi)'s landscape · Dihydroergotamine mesylate (Brekiya)'s landscape